title: Management of ruptured retinal arterial macroaneurysm with intravitreal bevacizumab.
abstract: The authors report the management of a ruptured retinal arterial macroaneurysm and associated hemorrhages with intravitreal injections of bevacizumab. A 79-year-old woman presented with a history of systemic arterial hypertension and a ruptured retinal arterial macroaneurysm with pre-retinal, intraretinal, and subretinal hemorrhages extending into the macula. Visual acuity at presentation was 20/400. The patient was treated with two intravitreal injections of bevacizumab at 4-week intervals. Steady clearing of the pre-retinal, intraretinal, and subretinal hemorrhages was observed with restoration of final visual acuity to 20/20 in the 12 months after the initial presentation. It appears that the novel application of intravitreal bevacizumab may be used in the treatment of ruptured retinal arterial macroaneurysm.
authors: Bascom Palmer Eye Institute, Department of Ophthalmology, University of Miami Miller School of Medicine, Palm Beach Gardens, Florida 33418 , USA.
authors: Golnaz
authors: G
authors: Javey
authors: Arlanna N
authors: AN
authors: Moshfeghi
authors: Andrew A
authors: AA
authors: Moshfeghi
mesh_terms: D000368:Aged; D017542:Aneurysm, Ruptured / Q000175:diagnosis / Q000188:drug therapy*; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D058449:Intravitreal Injections; D012161:Retinal Artery / Q000000981:diagnostic imaging / Q000187:drug effects*; D012166:Retinal Hemorrhage / Q000175:diagnosis / Q000188:drug therapy; D041623:Tomography, Optical Coherence; D014463:Ultrasonography; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology; D014823:Vitreous Hemorrhage / Q000175:diagnosis / Q000188:drug therapy
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab